

Author index

- Adcock, I.M., see Hayashi, R. (500) 51
- Advenier, C., see Frossard, N. (500) 453
- Aizenman, E., see Herin, G.A. (500) 101
- Antal, A., see Barthó, L. (500) 143
- Arckens, L., see Vercauteren, F.G.G. (500) 385
- Arulmani, U., MaassenVanDenBrink, A., Villalón, C.M. and Saxena, P.R.
Calcitonin gene-related peptide and its role in migraine pathophysiology (500) 315
- Baeyens, J.M., see Ocaña, M. (500) 203
- Barthó, L., Benkó, R., Patacchini, R., Pethő, G., Holzer-Petsche, U.,
Holzer, P., Lázár, Z., Undi, S., Illényi, L., Antal, A. and Horváth, Ö-P.
Effects of capsaicin on visceral smooth muscle: a valuable tool for sensory neurotransmitter identification (500) 143
- Basile, A.S., Lippa, A.S. and Skolnick, P.
Anxiolytic anxiolytics: can less be more? (500) 441
- Benkó, R., see Barthó, L. (500) 143
- Bergeron, J.J.M., see Vercauteren, F.G.G. (500) 385
- Biggio, F., see Follesa, P. (500) 413
- Biggio, G., see Follesa, P. (500) 413
- Brodde, O.-E. and Leineweber, K.
Autonomic receptor systems in the failing and aging human heart: similarities and differences (500) 167
- Candenas, M.L., see Pennefather, J.N. (500) 15
- Caria, S., see Follesa, P. (500) 413
- Cendán, C.M., see Ocaña, M. (500) 203
- Chataigneau, M., see Stoclet, J.-C. (500) 299
- Chataigneau, T., see Stoclet, J.-C. (500) 299
- Cho, C.H., see Koo, M.W.L. (500) 177
- Civelli, O., see Xu, Y.-L. (500) 243
- Cobos, E.J., see Ocaña, M. (500) 203
- Colado, M.I., see Green, A.R. (500) 3
- Cooper, S.J.
Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite (500) 37
- Couture, R. and Girolami, J.-P.
Putative roles of kinin receptors in the therapeutic effects of angiotensin I-converting enzyme inhibitors in diabetes mellitus (500) 467
- Dantzer, R.
Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity (500) 399
- Eisinger, D.A., see Schulz, R. (500) 487
- El Bedoui, J., see Stoclet, J.-C. (500) 299
- Endoh, M.
Force–frequency relationship in intact mammalian ventricular myocardium: physiological and pathophysiological relevance (500) 73
- Entrena, J.M., see Ocaña, M. (500) 203
- Finlayson, K., Witchel, H.J., McCulloch, J. and Sharkey, J.
Acquired QT interval prolongation and HERG: implications for drug discovery and development (500) 129
- Follesa, P., Biggio, F., Caria, S., Gorini, G. and Biggio, G.
Modulation of GABA_A receptor gene expression by allopregnanolone and ethanol (500) 413
- Forssell, H., see Hagelberg, N. (500) 187
- Freund, V., see Frossard, N. (500) 453
- Fride, E.
The endocannabinoid-CB₁ receptor system in pre- and postnatal life (500) 289
- Frossard, N., Freund, V. and Advenier, C.
Nerve growth factor and its receptors in asthma and inflammation (500) 453
- García-Sáinz, J.A. and Villalobos-Molina, R.
The elusive α_{1D} -adrenoceptor: molecular and cellular characteristics and integrative roles (500) 113
- Girolami, J.-P., see Couture, R. (500) 467
- Gorini, G., see Follesa, P. (500) 413
- Gosens, R., Zaagsma, J., Grootte Bromhaar, M., Nelemans, A. and Meurs, H.
Acetylcholine: a novel regulator of airway smooth muscle remodelling? (500) 193
- Green, A.R., O'Shea, E. and Colado, M.I.
A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response (500) 3
- Grootte Bromhaar, M., see Gosens, R. (500) 193
- Hagelberg, N., Jääskeläinen, S.K., Martikainen, I.K., Mansikka, H.,
Forssell, H., Scheinin, H., Hietala, J. and Pertovaara, A.
Striatal dopamine D2 receptors in modulation of pain in humans: a review (500) 187
- Hayashi, R., Wada, H., Ito, K. and Adcock, I.M.
Effects of glucocorticoids on gene transcription (500) 51
- Herin, G.A. and Aizenman, E.
Amino terminal domain regulation of NMDA receptor function (500) 101
- Hietala, J., see Hagelberg, N. (500) 187
- Holzer, P., see Barthó, L. (500) 143
- Holzer, P.
TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia (500) 231

- Holzer-Petsche, U., see Barthó, L. (500) 143
 Horváth, Ö.-P., see Barthó, L. (500) 143
- Illényi, L., see Barthó, L. (500) 143
 Ishiura, S., see Suo, S. (500) 159
 Ito, K., see Hayashi, R. (500) 51
- Jääskeläinen, S.K., see Hagelberg, N. (500) 187
 Jackson, V.R., see Xu, Y.-L. (500) 243
 Jakobs, K.H., see Oude Weernink, P.A. (500) 87
 Jancsó, G., see Nagy, I. (500) 351
- Kiss, J.P., see Sylvester Vizi, E. (500) 499
 Kleinert, H., Pautz, A., Linker, K. and Schwarz, P.M.
 Regulation of the expression of inducible nitric oxide synthase (500) 255
 Koo, M.W.L. and Cho, C.H.
 Pharmacological effects of green tea on the gastrointestinal system (500) 177
- Larsson, O.M., see Schousboe, A. (500) 281
 Lázár, Z., see Barthó, L. (500) 143
 Leineweber, K., see Brodde, O.-E. (500) 167
 Lendvai, B., see Sylvester Vizi, E. (500) 499
 Li, X.-Y., see Zhu, X.Z. (500) 221
 Linker, K., see Kleinert, H. (500) 255
 Lippa, A.S., see Basile, A.S. (500) 441
 Liu, J., see Zhu, X.Z. (500) 221
- MaassenVanDenBrink, A., see Arulmani, U. (500) 315
 Mansikka, H., see Hagelberg, N. (500) 187
 Martikainen, I.K., see Hagelberg, N. (500) 187
 Mayer, A., see Sylvester Vizi, E. (500) 499
 McCulloch, J., see Finlayson, K. (500) 129
 Meurs, H., see Gosens, R. (500) 193
 Millan, M.J.
 The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review (500) 371
 Mühl, H. and Pfeilschifter, J.
 Interleukin-18 bioactivity: a novel target for immunopharmacological anti-inflammatory intervention (500) 63
- Nabeshima, T., see Noda, Y. (500) 121
 Nagy, I., Sántha, P., Jancsó, G. and Urbán, L.
 The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology (500) 351
 Ndiaye, M., see Stoclet, J.-C. (500) 299
 Nebert, D.W. and Vesell, E.S.
 Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead (500) 267
 Nelemans, A., see Gosens, R. (500) 193
 Noda, Y. and Nabeshima, T.
 Opiate physical dependence and *N*-methyl-D-aspartate receptors (500) 121
- Oak, M.-H., see Stoclet, J.-C. (500) 299
 Ocaña, M., Cendán, C.M., Cobos, E.J., Entrena, J.M. and Baeyens, J.M.
 Potassium channels and pain: present realities and future opportunities (500) 203
 O'Shea, E., see Green, A.R. (500) 3
 Oude Weernink, P.A., Schmidt, M. and Jakobs, K.H.
 Regulation and cellular roles of phosphoinositide 5-kinases (500) 87
- Pablo Huidobro-Toro, J. and Verónica Donoso, M.
 Sympathetic co-transmission: the coordinated action of ATP and noradrenaline and their modulation by neuropeptide Y in human vascular neuroeffector junctions (500) 27
 Patacchini, R., see Barthó, L. (500) 143
 Patak, E., see Pennefather, J.N. (500) 15
 Pautz, A., see Kleinert, H. (500) 255
 Pennefather, J.N., Patak, E., Pinto, F.M. and Candenas, M.L.
 Mammalian tachykinins and uterine smooth muscle: the challenge escalates (500) 15
 Pertovaara, A., see Hagelberg, N. (500) 187
 Pethő, G., see Barthó, L. (500) 143
 Pfeilschifter, J., see Mühl, H. (500) 63
 Pinto, F.M., see Pennefather, J.N. (500) 15
 Przewlocki, R.
 Opioid abuse and brain gene expression (500) 331
- Quirion, R., see Vercauteren, F.G.G. (500) 385
- Rózsa, B., see Sylvester Vizi, E. (500) 499
- Sántha, P., see Nagy, I. (500) 351
 Sarup, A., see Schousboe, A. (500) 281
 Saxena, P.R., see Arulmani, U. (500) 315
 Scheinin, H., see Hagelberg, N. (500) 187
 Schini-Kerth, V.B., see Stoclet, J.-C. (500) 299
 Schmidt, M., see Oude Weernink, P.A. (500) 87
 Schousboe, A., Larsson, O.M., Sarup, A. and White, H.S.
 Role of the betaine/GABA transporter (BGT-1/GAT2) for the control of epilepsy (500) 281
 Schulz, R., Eisinger, D.A. and Wehmeyer, A.
 Opioid control of MAP kinase cascade (500) 487
 Schwarz, P.M., see Kleinert, H. (500) 255
 Sharkey, J., see Finlayson, K. (500) 129
 Skolnick, P., see Basile, A.S. (500) 441
 Stoclet, J.-C., Chataigneau, T., Ndiaye, M., Oak, M.-H., El Bedoui, J., Chataigneau, M. and Schini-Kerth, V.B.
 Vascular protection by dietary polyphenols (500) 299
 Suo, S., Ishiura, S. and Van Tol, H.H.M.
 Dopamine receptors in *C. elegans* (500) 159
 Sylvester Vizi, E., Rózsa, B., Mayer, A., Kiss, J.P., Zelles, T. and Lendvai, B.
 Further evidence for the functional role of nonsynaptic nicotinic acetylcholine receptors (500) 499
- Undi, S., see Barthó, L. (500) 143
 Urbán, L., see Nagy, I. (500) 351
- Van Tol, H.H.M., see Suo, S. (500) 159
 Vandesande, F., see Vercauteren, F.G.G. (500) 385
 Vercauteren, F.G.G., Bergeron, J.J.M., Vandesande, F., Arckens, L. and Quirion, R.
 Proteomic approaches in brain research and neuropharmacology (500) 385
 Verónica Donoso, M., see Pablo Huidobro-Toro, J. (500) 27
 Vesell, E.S., see Nebert, D.W. (500) 267
 Villalobos-Molina, R., see García-Sáinz, J.A. (500) 113
 Villalón, C.M., see Arulmani, U. (500) 315
- Wada, H., see Hayashi, R. (500) 51
 Wehmeyer, A., see Schulz, R. (500) 487
 White, H.S., see Schousboe, A. (500) 281

- Whittle, B.J.R.
 Mechanisms underlying intestinal injury induced by anti-inflammatory
 COX inhibitors (500) 427
- Witchel, H.J., see Finlayson, K. (500) 129
- Xu, Y.-L., Jackson, V.R. and Civelli, O.
 Orphan G protein-coupled receptors and obesity (500) 243
- Zaagsma, J., see Gosens, R. (500) 193
- Zelles, T., see Sylvester Vizi, E. (500) 499
- Zhu, X.Z., Li, X.-Y. and Liu, J.
 Recent pharmacological studies on natural products in China (500) 221